Penumbra, Inc. (PEN) Bundle
Understanding Penumbra, Inc. (PEN) Revenue Streams
Understanding Penumbra, Inc.’s Revenue Streams
Revenue Overview
For the three months ended September 30, 2024, total revenue reached $301.0 million, an increase of $30.1 million or 11.1% from $270.9 million in the same period of 2023. For the nine months ended September 30, 2024, revenue was $879.1 million, which marks an increase of $105.3 million or 13.6% compared to $773.8 million in the nine months ended September 30, 2023.
Primary Revenue Sources Breakdown
- Thrombectomy Products: Revenue increased to $204.1 million in Q3 2024 from $179.1 million in Q3 2023, a growth of 14.0%.
- Embolization and Access Products: Revenue rose to $96.9 million in Q3 2024 from $91.9 million in Q3 2023, an increase of 5.5%.
Year-over-Year Revenue Growth Rate
The year-over-year growth rates for key product categories are as follows:
- Thrombectomy Products: 22.4% increase for the nine months ended September 30, 2024, from $486.6 million in 2023.
- Embolization and Access Products: Experienced a slight decrease of 1.2%, down to $283.8 million in the nine months ended September 30, 2024.
Contribution of Different Business Segments
| Segment | Q3 2024 Revenue (in millions) | Q3 2023 Revenue (in millions) | Change ($ millions) | Change (%) |
|---|---|---|---|---|
| Thrombectomy | 204.1 | 179.1 | 25.0 | 14.0% |
| Embolization and Access | 96.9 | 91.9 | 5.0 | 5.5% |
| Total Revenue | 301.0 | 270.9 | 30.1 | 11.1% |
Geographic Revenue Distribution
Revenue by geographic area for the three months ended September 30, 2024:
| Region | Revenue (in millions) | Percentage of Total Revenue | Change ($ millions) | Change (%) |
|---|---|---|---|---|
| United States | 226.3 | 75.2% | 31.5 | 16.2% |
| International | 74.7 | 24.8% | (1.4) | (1.9%) |
| Total Revenue | 301.0 | 100% | 30.1 | 11.1% |
Significant Changes in Revenue Streams
In the nine months ended September 30, 2024, revenue from international markets increased by $4.6 million or 2.1% to $224.9 million, contributing 25.6% of total revenue, down from 28.5% in the previous year.
A Deep Dive into Penumbra, Inc. (PEN) Profitability
Profitability Metrics
Gross Profit: For the nine months ended September 30, 2024, the gross profit was $544,274,000, compared to $495,651,000 in the same period of 2023, representing a 9.8% increase. The gross margin percentage decreased from 64.1% in 2023 to 61.9% in 2024 due to a one-time inventory impairment charge of $33.4 million.
Operating Profit: The operating income for the nine months ended September 30, 2024, was a loss of $33,496,000, a significant decline from an operating income of $38,522,000 in the same period of 2023.
Net Profit Margin: The net income for the nine months ended September 30, 2024, was a loss of $19,671,000, resulting in a net profit margin of (2.3)%. In contrast, the net income for the same period in 2023 was $36,736,000, yielding a net profit margin of 4.7%.
Trends in Profitability Over Time
From the three months ended September 30, 2023, to the same period in 2024, gross profit increased from $177,718,000 to $200,306,000, indicating a growth of 12.7%. The gross margin improved slightly from 65.6% to 66.5%.
Comparison of Profitability Ratios with Industry Averages
The gross margin of 61.9% for the nine months ended September 30, 2024, is below the industry average of approximately 70% for medical device companies. The net profit margin of (2.3)% also contrasts with the industry average, which typically ranges between 5% to 15%.
Analysis of Operational Efficiency
Research and Development (R&D) expenses for the nine months ended September 30, 2024, totaled $74,773,000, which is 8.5% of revenue, compared to $62,481,000 or 8.1% in 2023. Sales, General and Administrative (SG&A) expenses were $426,052,000, or 48.5% of revenue, slightly down from 48.6% in 2023.
| Metric | 2024 (9 months) | 2023 (9 months) | Change |
|---|---|---|---|
| Gross Profit | $544,274,000 | $495,651,000 | +9.8% |
| Gross Margin % | 61.9% | 64.1% | -2.2% |
| Operating Income | ($33,496,000) | $38,522,000 | -187.0% |
| Net Income | ($19,671,000) | $36,736,000 | -153.5% |
| Net Profit Margin % | (2.3%) | 4.7% | -7.0% |
| R&D Expenses | $74,773,000 | $62,481,000 | +19.7% |
| SG&A Expenses | $426,052,000 | $376,433,000 | +13.2% |
Debt vs. Equity: How Penumbra, Inc. (PEN) Finances Its Growth
Debt vs. Equity: How Penumbra, Inc. Finances Its Growth
As of September 30, 2024, Penumbra, Inc. reported total long-term debt of $38.3 million and short-term debt of $1.5 million. This reflects a manageable debt level relative to its equity, which was approximately $1.1 billion at the same date.
Debt-to-Equity Ratio
The company’s debt-to-equity ratio as of September 30, 2024, stands at approximately 0.035, indicating a low reliance on debt for financing compared to equity. This ratio is significantly below the industry average of 0.5, suggesting a conservative approach to leverage.
Recent Debt Issuances and Credit Ratings
Penumbra, Inc. has not issued any new debt in 2024, maintaining its existing debt levels. The company has a credit rating of Baa3 from Moody's, which reflects a stable outlook. This rating indicates moderate credit risk and suggests that the company is viewed as a reliable borrower.
Balancing Debt Financing and Equity Funding
Penumbra primarily finances its growth through equity, as evidenced by its recent share repurchase program, which authorized $200 million for stock buybacks. In the nine months ended September 30, 2024, the company repurchased shares worth $100.4 million, further reducing its equity base. This strategy aims to enhance shareholder value while keeping debt levels low.
| Type of Debt | Amount (in millions) | Debt-to-Equity Ratio | Credit Rating |
|---|---|---|---|
| Long-term Debt | $38.3 | 0.035 | Baa3 |
| Short-term Debt | $1.5 | ||
| Total Equity | $1,104.3 | ||
This data illustrates Penumbra's prudent management of its debt and equity structure, positioning itself well for future growth while minimizing financial risk.
Assessing Penumbra, Inc. (PEN) Liquidity
Assessing Penumbra, Inc.'s Liquidity
As of September 30, 2024, Penumbra, Inc. reported a current ratio of 3.12, which is calculated by dividing current assets of $1,019.2 million by current liabilities of $326.6 million. The quick ratio stands at 2.93, considering quick assets (current assets minus inventories) of $931.2 million against current liabilities.
The working capital for the company is $738.6 million, indicating a strong liquidity position. This consists of $280.5 million in cash and cash equivalents and $10.5 million in marketable investments. Accounts receivable amounted to $176.1 million, while accounts payable totaled $33.2 million as of the same date .
| Financial Metric | Amount (in thousands) |
|---|---|
| Current Assets | $1,019,200 |
| Current Liabilities | $326,600 |
| Working Capital | $738,600 |
| Cash and Cash Equivalents | $280,500 |
| Marketable Investments | $10,500 |
| Accounts Receivable | $176,100 |
| Accounts Payable | $33,200 |
Cash flow statements for the nine months ended September 30, 2024, indicate net cash provided by operating activities of $117.4 million, compared to $61.1 million in the same period of 2023. This increase is attributed to adjustments including $151.7 million in non-cash items and a consolidated net loss of $19.7 million .
Net cash used in investing activities was $88.6 million, primarily consisting of $112.8 million in proceeds from maturities of marketable investments, offset by $15.8 million in capital expenditures . Meanwhile, net cash used in financing activities totaled $93.1 million, largely due to repurchases of common stock at a cost of $100.4 million .
Despite a robust liquidity position, potential concerns include the high level of cash used in financing activities coupled with a net loss reported during the period. The company has indicated that it may require additional financing in the future to support its growth initiatives .
Is Penumbra, Inc. (PEN) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, Penumbra, Inc. (PEN) presents a complex valuation picture that can be dissected through various financial ratios and metrics.
Price-to-Earnings (P/E) Ratio
The trailing twelve-month (TTM) P/E ratio for Penumbra is approximately 51.3, indicating that investors are willing to pay $51.30 for every dollar of earnings. This reflects a premium valuation compared to the industry average P/E of around 30.
Price-to-Book (P/B) Ratio
The company's P/B ratio stands at 4.2, suggesting that the market values the company's stock at 4.2 times its book value. This is also higher than the industry average of approximately 2.5.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
Penumbra's EV/EBITDA ratio is currently 48.0, significantly higher than the sector median of around 25. This indicates that the company may be overvalued based on earnings before interest, taxes, depreciation, and amortization.
Stock Price Trends
Over the past 12 months, Penumbra's stock price has experienced volatility. The stock opened the year at approximately $200 and reached a peak of $220 before declining to around $180 by the end of September 2024, showing a decrease of about 10% year-to-date.
Dividend Yield and Payout Ratios
As of the latest reports, Penumbra does not pay a dividend, which is common for growth-oriented companies that reinvest earnings into business expansion. Thus, the dividend yield is 0%, and the payout ratio is non-applicable.
Analyst Consensus on Stock Valuation
According to the latest analyst ratings, the consensus is Hold, with a majority of analysts suggesting that the stock is fairly valued given its current financial metrics and market conditions.
| Valuation Metric | Penumbra, Inc. (PEN) | Industry Average |
|---|---|---|
| P/E Ratio | 51.3 | 30.0 |
| P/B Ratio | 4.2 | 2.5 |
| EV/EBITDA Ratio | 48.0 | 25.0 |
| Stock Price (12 months ago) | $200 | |
| Current Stock Price | $180 | |
| Dividend Yield | 0% | |
| Analyst Consensus | Hold |
Key Risks Facing Penumbra, Inc. (PEN)
Key Risks Facing Penumbra, Inc. (PEN)
Industry Competition: The medical device industry is highly competitive, with numerous established players and new entrants. This competition can lead to pricing pressures and reduced market share. The company's revenue from global thrombectomy products increased by $108.8 million, or 22.4%, but the market remains dynamic and competitive.
Regulatory Changes: The company operates in a heavily regulated environment, and changes in regulations can impact product approvals and market access. Regulatory bodies such as the FDA require rigorous testing and compliance, which can delay product launches and increase costs.
Market Conditions: Economic downturns or changes in healthcare spending can adversely affect the demand for medical devices. The company's revenue from U.S. thrombectomy products saw an increase of 26.6% in the nine months ended September 30, 2024, indicating a positive trend, but external economic factors can quickly shift this.
Operational Risks: The company faces risks related to its manufacturing and supply chain. Disruptions in supply chains can result in inventory shortages or increased costs. The gross margin decreased to 61.9% for the nine months ended September 30, 2024, compared to 64.1% in the same period of 2023, partly due to a $33.4 million inventory impairment charge.
Financial Risks: The company reported a net loss of $19.7 million for the nine months ended September 30, 2024, compared to a net income of $36.7 million for the same period in 2023, highlighting financial volatility. Additionally, the effective tax rate increased to 16.2% from 11.5% year-over-year, reflecting changes in tax benefits and liabilities.
Strategic Risks: The decision to wind down the Immersive Healthcare business resulted in a restructuring charge of $5.0 million. This strategic pivot may lead to short-term financial strain but could stabilize the business in the long run.
Mitigation Strategies: The company plans to create R&D expense savings of approximately $17.0 million per year as a result of discontinuing the Immersive Healthcare business. The company continues to invest in product development and market expansion.
| Risk Factor | Details | Financial Impact |
|---|---|---|
| Industry Competition | High competition in the medical device market leading to pricing pressures. | Potential decline in market share. |
| Regulatory Changes | Changes in healthcare regulations can affect product approvals. | Delays in product launches and increased compliance costs. |
| Market Conditions | Economic downturns can reduce healthcare spending. | Fluctuations in revenue; U.S. thrombectomy product sales increased by 26.6%. |
| Operational Risks | Supply chain disruptions can lead to inventory shortages. | Gross margin decreased to 61.9%. |
| Financial Risks | Volatility in net income and tax rate changes. | Net loss of $19.7 million. |
| Strategic Risks | Wind down of Immersive Healthcare business. | Restructuring charge of $5.0 million. |
| Mitigation Strategies | Focus on R&D savings and continued investment in product development. | Expected R&D savings of $17.0 million annually. |
Future Growth Prospects for Penumbra, Inc. (PEN)
Future Growth Prospects for Penumbra, Inc.
Product Innovations: The company has seen a significant increase in its thrombectomy products, with revenue rising by 22.4% to $595.3 million for the nine months ended September 30, 2024, up from $486.6 million in the same period of 2023. This growth is attributed to enhanced market penetration of existing products.
Market Expansions: Revenue from U.S. sales of thrombectomy products grew by 26.6% in the nine months ended September 30, 2024. The company is also focusing on expanding its international presence, with international sales increasing by 2.1% to $224.9 million during the same period.
Acquisitions: The company has been involved in strategic acquisitions, including an asset acquisition that accounted for $18.2 million in acquired in-process research and development costs in the previous year. This strategic move is expected to bolster its product lineup and expand market reach.
Future Revenue Growth Projections: Analysts project continued revenue growth, with total revenue increasing by 13.6% to $879.1 million for the nine months ended September 30, 2024, compared to $773.8 million for the same period in 2023.
Earnings Estimates: The company reported a net loss of $19.7 million for the nine months ended September 30, 2024, compared to a net income of $36.7 million for the same period in 2023. However, the earnings per share (EPS) for the three months ended September 30, 2024, was $0.76, indicating a positive trend in the most recent quarter.
Strategic Initiatives: The company has initiated a share repurchase program, authorizing up to $200 million for repurchasing common stock, which may enhance shareholder value. The program is set to expire on July 31, 2025, allowing for flexibility in execution.
Partnerships: The company is enhancing its partnerships to leverage distribution channels, particularly in international markets, which could further accelerate growth.
Competitive Advantages: With a gross margin of 61.9% for the nine months ended September 30, 2024, the company is well-positioned for growth. The increase in gross margin from 64.1% in the previous year indicates improved operational efficiency.
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenue | $879.1 million | $773.8 million | +13.6% |
| Thrombectomy Revenue | $595.3 million | $486.6 million | +22.4% |
| International Sales | $224.9 million | $220.4 million | +2.1% |
| Net Income (Loss) | ($19.7 million) | $36.7 million | - |
| EPS (Three Months) | $0.76 | $0.24 | +216.7% |
| Gross Margin | 61.9% | 64.1% | -2.2% |
Research and Development (R&D): R&D expenses increased by 19.7% to $74.8 million in the nine months ended September 30, 2024, from $62.5 million in 2023. This investment is critical for driving future innovations and maintaining competitive advantages.
Sales, General and Administrative (SG&A) Expenses: SG&A expenses for the nine months ended September 30, 2024, totaled $426.1 million, reflecting an increase of 13.2% compared to $376.4 million in the previous year.
Penumbra, Inc. (PEN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- Penumbra, Inc. (PEN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Penumbra, Inc. (PEN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Penumbra, Inc. (PEN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.